Navigation Links
Oncolytics Biotech(R) Inc. Collaborators Update Combination REOLYSIN(R) and Docetaxel Trial Results at Replicating Oncolytic Virus Meeting
Date:3/20/2009

bination with a standard dosage of docetaxel. Eligible patients included those who have been diagnosed with advanced or metastatic solid tumours that are refractory (have not responded) to standard therapy or for which no curative standard therapy exists.

The poster presentation will be available on the Oncolytics website today at www.oncolyticsbiotech.com.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), the Company's analysis of the results of the REOLYSIN(R)/docetaxel trial and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize RE
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at AACR Annual Meeting
2. Oncolytics Biotech(R) Inc. Reports Highlights and Financial Results for 2008
3. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering North America
4. Oncolytics Biotech Inc. Announces Issuance of 31st U.S. Patent
5. Oncolytics Biotech Inc.s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
6. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
8. Oncolytics Biotech Inc. Announces U.S. Phase II Sarcoma Clinical Trial Conference Call
9. Oncolytics Biotech Inc. Announces 2008 Third Quarter Results
10. Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial
11. Oncolytics Biotech Inc. Announces Clinical Update Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... news release is available in German . ... crystal around several quantum dots in a semiconductor layer. Quantum ... consequence of atomic processes. If a short laser pulse is ... and the quantum dot experiences a change in the electromagnetic ... down the emission of light by the dot. As soon ...
(Date:9/30/2014)... of one of nature,s most efficient light-harvesting structures, ... by Alejandro Briseno of the University of Massachusetts ... long-sought polymer architecture to boost power-conversion efficiency of ... , Briseno, with colleagues and graduate students ... and Dresden University of Technology, Germany, report in ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Shimadzu ... extensometer, an easy-to-use and highly precise tool for ... with considerable elongation. With 1000-mm maximum movement distance, ... percent for a gauge length of 10 mm. ... measurement accuracy above 50-mm stroke and within +/- ...
(Date:9/30/2014)... Proove Biosciences , the commercial and research ... new genetic test built upon research from their published ... will provide physicians with an objective way to understand ... stratified between individuals. With this new test, physicians will ... genetic predisposition that will affect their pain tolerance. , ...
Breaking Biology Technology:Ultrafast remote switching of light emission 2Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3
... , Feb. 3 ERT (Nasdaq: ERES ), announced ... full year 2009 on Thursday, February 25, 2010 , after the ... at 5:00 PM EST that day. , For the ... United States or 1-412-858-4600 when calling internationally. There will be a ...
... GENEVA , February 3 Viroblock ... anti-viral products, today,announced that Dr. Jamie Paterson will join ... Jamie Paterson , a British national, can look back at 20 ... was,Chief Commercial Officer at Neurim Pharmaceuticals. During his 18 years at,Procter ...
... Molecular Imaging Summit wrapped up today in Albuquerque, ... energy looking ahead. Nanotechnology is a quickly ... for applying technology in highly targeted ways. For ... target diseaseand treat many common and devastating diseases ...
Cached Biology Technology:ERT to Announce Fourth Quarter and Full Year 2009 Results on February 25, 2010 2Viroblock SA Hires Dr. Jamie Paterson as CEO and Closes Financing Round 2SNM's nanomedicine summit advances molecular imaging 2SNM's nanomedicine summit advances molecular imaging 3
(Date:10/1/2014)... take a healthy salad up a level by growing ... in leafy greens. , "In the long run, one ... the salad or making a pill from the plant ... at Case Western Reserve School of Medicine and leader ... cancer organization is funding the research with a three-year, ...
(Date:9/30/2014)... Mediterranean each year, but its deep-blue waters host ... 1,000 alien species, including fish, crustaceans, and algae ... activities. In the open-access journal Frontiers in ... analyzed data from a new information system developed ... introduction of alien species has changed the native ...
(Date:9/30/2014)... most comprehensive assessment conducted by the Ocean Health ... of 100 in overall health. In addition, for ... and the 15 ocean regions beyond national jurisdiction ... a healthy climate, safeguarding biodiversity and providing sustainable ... of the index, a partnership led by scientists ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Biodiversity in the Mediterranean is threatened by alien species 2Rating the planet's oceans 2Rating the planet's oceans 3
... release is available in Spanish . , Barcelona, ... been discovered that neutrophils exist in the spleen without there ... group on the Biology of B Cells of IMIM (Hospital ... Sinai in New York, has also made it possible to ...
... imaging technologies and their contrast agents chemicals used during ... exposure to radiation or heavy metals, which present potential health ... applied. In an effort to mitigate these drawbacks, new research ... an iron-based contrast agent so that it only interacts with ...
... Calif., December 23, 2011 John C. Reed, M.D., Ph.D., ... Institute (Sanford-Burnham), have been named as Fellows of the American ... AAAS Fellow is an honor bestowed upon AAAS members by ... announced today in the AAAS News & Notes section of ...
Cached Biology News:Discovered the existence of neutrophils in the spleen 2Penn engineers develop more effective MRI contrast agent for cancer detection 2Penn engineers develop more effective MRI contrast agent for cancer detection 3AAAS and Sanford-Burnham announce 2011 fellows 2
... is a derivative of Taq DNA polymerase. ... aquaticus DNA polymerase. Expressed from a gene ... Met236, bypassing the 5'-3' exonuclease domain of ... a highly active and even more heat-stable ...
... Neogens enzyme-linked immunosorbent assay (ELISA) test ... screening devices for the detection of drugs ... kits are intended for forensic use only. ... be confirmed by a quantitative method such ...
... protein ribonuclease inhibitor that noncovalently binds and inactivates ... seen with RNase 1, T1, T2, H, U1, ... placental ribonuclease inhibitor in that it has a ... release active RNase in the absence of DTT ...
...
Biology Products: